BIODOL THERAPEUTICS
An Innovative Treatment for Chronic Pain
An Innovative Treatment for Chronic Pain
BIODOL THERAPEUTICS is a biotech company founded in 2015 and based in France. Their slogan, "An Innovative Treatment for Chronic Pain," encapsulates their innovative approach. The company's focus is on developing first-in-class compounds to address chronic pain, leveraging their breakthrough discovery of the target FLT3, a master hub protein in initiating and maintaining neuropathic pain as published in Nature Communications 2018. Additionally, Biodol's research indicates that their FLT3 breakthrough platform has the potential to contribute to the solution of the Opioid Crisis, though this aspect is currently patented but unpublished. With a series of FLT3 selective small-molecule extracellular antagonists, Biodol's FLT3 Technological Platform is safeguarded by 5 patents. This underscores the company's commitment to bringing innovative and impactful solutions to the field of health and wellness.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Funding Round | €7.00M | 2 |
|
21 May 2024 |
| Series A | €4.50M | 1 |
|
31 Aug 2020 |
No recent news or press coverage available for BIODOL THERAPEUTICS.
We care about your data, and we'd love to use cookies make your experience better.
